PTC
MACK

Private Trust Company’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Private Trust Company’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-34
Closed -$2K – 1802
2013
Q2 		$2K Buy
+34
New +$1.49K ﹤0.01% 1438

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Private Trust Company's MACK Position: Q3 2013 in Review

Private Trust Company sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2013, closing a stake of 34 shares — an estimated $2K sold.

Private Trust Company first reported a position in MACK in Q2 2013 and held it in 1 quarter. The position peaked at $2K in Q2 2013. 95 funds tracked by Wall St. Rank hold MACK as of Q3 2013.

  • Private Trust Company reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2013 after selling out during the quarter.
  • Private Trust Company sold 34 Merrimack Pharmaceuticals, Inc. shares in Q3 2013, an estimated $2K.
  • Private Trust Company first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 1 quarter.
  • Private Trust Company's Merrimack Pharmaceuticals, Inc. position peaked at $2K in Q2 2013.
  • 95 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2013.

Based on Private Trust Company's 13F filing for Q3 2013, filed 7 Oct 2013.